Ottawa, ON /Business Wire/ September 28, 2020 / –Avivagen Inc.  (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”),a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce that it has received a new purchase order for OxC-beta Livestock from Industrias Melder in Mexico through Avivagen’s Mexican consultant Meyenberg International Group.  Following its initial two tonne purchase order in May, Industrias Melder has delivered a purchase order for two tonnes of OxC-betaTM Livestock every two months, commencing in December 2020 and continuing for 10 months, for a total amount of ten tonnes.

“We are very pleased to continue to grow our mutually-beneficial relationship with Industrias Melder in Mexico,” says Kym Anthony, Chief Executive Officers, Avivigaen Inc. “As our largest North American client currently, Industrias Melder has seen first-hand the benefits that OxC-betaTM Livestock can provide, and this substantial commitment is further evidence of the value of the technology in promoting improved immune-system performance in livestock. The company’s application of OxC-betaTM to its commercial dairy production is further evidence of the new value streams in which the technology can be applied with great impact.”

Melder will be utilizing OxC-betaTM Livestock with its dairy, swine and poultry customers.

This purchase order further illustrates the significance of the two positive trials of the use of OxC-beta™ Livestock in commercial dairy production conducted earlier this year by a Mexican dairy farm which is a customer of Industrias Melder (see Avivagen News Release, May 20, 2020). The tests evaluated OxC-beta for the ability to improve animal health, productivity and milk quality. Of significant note, a large and well known Fortune 100 global dairy processor that purchases the farm’s milk recognized the farm with three separate financial awards for the improvements in milk yield, quality, and reduced bacterial levels achieved during the test.

With annual feed sales of more than 36 million tonnes[i] Mexico represents a fast-growing market for feed production. The purchase order is non-exclusive in nature, affording Avivagen the opportunity to continue ongoing discussions with other large distributors in the region.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals.  Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and on the OTCQB Exchange in the U.S. under the symbol VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Mexico, Australia, Brazil and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions aim”, anticipate”, appear”, believe”, consider”, could”, estimate”, expect”, if”, intend”, goal”, hope”, likely”, may”, plan”, possibly”, potentially”, pursue”, seem”, should”, whether”, will”, would” and similar expressions. Statements set out in this news release relating to future shipments of product based on the above referenced purchase order,  the continued distribution and acceptance of Avivagen’s technology, anticipated growth in demand for Avivagen’s products,  the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded, the size of market opportunities and the potential for a longer term relationship with Industrias Melder are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, these initial orders may not result in new orders for Avivagens products,  despite receipt of the purchase order delivery or  fulfilment of orders of product could be delayed for a number of reasons, some of which are outside of Avivagen’ s control, which could result in anticipated revenues from such sales being delayed or in the most serious cases eliminated, actions taken by Avivagen’ s customers and factors affecting the business and financial viability of Avivagen’ s customers can have a negative impact on the expectation of future sales and revenues, demand for Avivagens products may not continue to grow and could decline, Avivagens products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics in livestock feeds, new market access may not occur in the timeline or manner expected by Avivagen, the market opportunities may not be as large as Avivagen anticipates and a longer term relationship with Industrias Melder may not be achieved due to many factors, many of which are outside of Avivagens control.  Trial results described above may not be indicative of anticipated results of using Avivagen’s products in all cases.  Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagens most recent managements discussion and analysis of financial condition available at Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

Avivagen Inc.

Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Phone: 416-540-0733

Kym Anthony
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164


Copyright © 2020 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.